People with multiple sclerosis (MS) treated with injectable, oral or infusion disease-modifying therapies (DMTs) show few differences in health-related quality of life (HRQoL) outcomes.
Why this matters
Although many studies have examined the effect of DMTs on disease activity in people with MS, patient-reported outcomes (PROs) can provide a better understanding of the impact of treatment on peoples’ lives.
Longer-term studies are needed to understand the relationship between HRQoL and DMT initiation and transition.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.